268 related articles for article (PubMed ID: 28893236)
1. Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer.
Panje C; Riesterer O; Glanzmann C; Studer G
BMC Cancer; 2017 Sep; 17(1):643. PubMed ID: 28893236
[TBL] [Abstract][Full Text] [Related]
2. Volumetric staging in oropharyngeal cancer patients treated with definitive IMRT.
Studer G; Glanzmann C
Oral Oncol; 2013 Mar; 49(3):269-76. PubMed ID: 23089460
[TBL] [Abstract][Full Text] [Related]
3. Survival impact of pre-treatment neutrophils on oropharyngeal and laryngeal cancer patients undergoing definitive radiotherapy.
Sumner WA; Stokes WA; Oweida A; Berggren KL; McDermott JD; Raben D; Abbott D; Jones B; Gan G; Karam SD
J Transl Med; 2017 Aug; 15(1):168. PubMed ID: 28764811
[TBL] [Abstract][Full Text] [Related]
4. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy.
Carpén T; Saarilahti K; Haglund C; Markkola A; Tarkkanen J; Hagström J; Mattila P; Mäkitie A
Strahlenther Onkol; 2018 Aug; 194(8):759-770. PubMed ID: 29774396
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy.
Ng SP; Bahig H; Jethanandani A; Sturgis EM; Johnson FM; Elgohari B; Gunn GB; Ferrarotto R; Phan J; Rosenthal DI; Frank SJ; Fuller CD; Garden AS
Br J Cancer; 2021 Feb; 124(3):628-633. PubMed ID: 33051590
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of the tumor volume reduction rate in head-and-neck cancer during definitive intensity-modulated radiotherapy for organ preservation.
Yang SN; Liao CY; Chen SW; Liang JA; Tsai MH; Hua CH; Lin FJ
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1096-103. PubMed ID: 20605362
[TBL] [Abstract][Full Text] [Related]
9. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the prognostic role of neutrophil-to-lymphocyte ratio following complete resection of thymoma.
Muriana P; Carretta A; Ciriaco P; Bandiera A; Negri G
J Cardiothorac Surg; 2018 Nov; 13(1):119. PubMed ID: 30454002
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
Ye L; Oei RW; Kong F; Xu T; Shen C; Wang X; He X; Kong L; Hu C; Ying H
Eur Arch Otorhinolaryngol; 2018 May; 275(5):1309-1317. PubMed ID: 29589142
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of the ratio of neutrophils to lymphocytes before and after intensity modulated radiotherapy for patients with nasopharyngeal carcinoma.
Liu J; Wei C; Tang H; Liu Y; Liu W; Lin C
Medicine (Baltimore); 2020 Jan; 99(2):e18545. PubMed ID: 31914029
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer.
Wang J; Kalhor N; Hu J; Wang B; Chu H; Zhang B; Guan Y; Wu Y
PLoS One; 2016; 11(10):e0163397. PubMed ID: 27695079
[TBL] [Abstract][Full Text] [Related]
14. [Neutrophil to lymphocyte ratio in peripheral blood: a novel independent prognostic factor in patients with head and neck squamous cell carcinoma].
Wu F; Wu LL; Zhu LX
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):29-32. PubMed ID: 28104030
[No Abstract] [Full Text] [Related]
15. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
Sun J; Ning H; Sun J; Qu X
Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
[TBL] [Abstract][Full Text] [Related]
16. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
[No Abstract] [Full Text] [Related]
18. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
[TBL] [Abstract][Full Text] [Related]
19. Two-step Intensity-modulated Radiation Therapy for Oropharyngeal Cancer: Initial Clinical Experience and Validation of Clinical Staging.
Tatebe H; Doi H; Ishikawa K; Kawakami H; Yokokawa M; Nakamatsu K; Kanamori S; Shibata T; Kitano M; Nishimura Y
Anticancer Res; 2018 Feb; 38(2):979-986. PubMed ID: 29374730
[TBL] [Abstract][Full Text] [Related]
20. Volumetric staging in radiotherapy for oropharyngeal cancers.
Miszczyk M; Staniewska E; Jabłońska I; Lipka-Rajwa A; Stawiski K; Tarnawski R
Tumori; 2022 Dec; 108(6):586-591. PubMed ID: 34628998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
